STOK
Stoke Therapeutics, Inc.
STOK lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
STOK Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
STOK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
STOK PE Valuation
STOK has no meaningful PE right now: it lost money over the past year.
STOK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STOK's losses to grow, with revenue growing. However, they disagree widely on these estimates.
STOK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.77 | -639% |
| Q2 2026 | -$3.34 | -480% |
| Q1 2026 | -$2.81 | -443% |
| Q4 2025 | -$0.12 | +$1.53 |
| Q3 2025 | $0.70 | +$2.81 |
| Q2 2025 | $0.88 | +$3.07 |
| Q1 2025 | $0.82 | +$3.24 |
| Q4 2024 | -$1.65 | +$0.73 |
STOK has swung to a loss: it lost $3.77 per share over the past year, after a profit the year before.
STOK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | +5.9% |
| Q2 2026 | $9.3M | -33% |
| Q1 2026 | $6.2M | -96% |
| Q4 2025 | $1.4M | -94% |
| Q3 2025 | $10.6M | +117% |
| Q2 2025 | $13.8M | +186% |
| Q1 2025 | $158.6M | +3661% |
| Q4 2024 | $22.6M | +707% |
STOK's revenue is recovering but still below its 2025 peak: $11M last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -687% | -282 points |
| Q2 2026 | -702% | -504 points |
| Q1 2026 | -858% | -928 points |
| Q4 2025 | -4382% | -4322 points |
| Q3 2025 | -405% | +208 points |
| Q2 2025 | -198% | +410 points |
| Q1 2025 | 70% | +743 points |
| Q4 2024 | -60% | +996 points |
STOK's operating margin was −687% last quarter, down 282 points from the same quarter a year ago.
STOK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$65.5M | -$35M |
| Q2 2026 | -$58.6M | -$33M |
| Q1 2026 | -$60.9M | -146% |
| Q4 2025 | -$30.7M | -$7.5M |
| Q3 2025 | -$30.5M | -$8.8M |
| Q2 2025 | -$25.6M | -$8.1M |
| Q1 2025 | $131.7M | +$156.3M |
| Q4 2024 | -$23.2M | -$2.4M |
STOK has burned cash in almost every quarter: −$216M over the past year, against $52M the year before.
STOK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +2.3M shares |
| 1 year | +17% | +9.8M shares |
| 3 years | +54% | +24.1M shares |
| 5 years | +86% | +31.6M shares |
| Available history | +108% | +35.5M shares |
STOK has 68M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
STOK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.9x | Net Cash |
| Q2 2025 | -2.4x | Net Cash |
| Q1 2025 | -6.8x | Net Cash |
STOK has more cash than debt.
STOK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 36.1 | Neutral |
STOK's weekly RSI is 43 (neutral) and its Stochastic is 36 (neutral).
STOK PE vs Healthcare Sector
| Metric | STOK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
STOK has no meaningful PE right now: it lost money over the past year.
STOK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.4 | 3.1% above |
| 20 week MA | $28.5 | 8% below |
| 50 week MA | $30.7 | 15% below |
| 100 week MA | $22.9 | 14% above |
| 200 week MA | $16.2 | 61% above |
STOK's trend is mixed: it's above three of its five weekly moving averages, and 61% above its 200-week average.
STOK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.6 | $58.3 | +119% |
| 2021 | $58.3 | $21.6 | -63% |
| 2022 | $21.6 | $8.30 | -62% |
| 2023 | $8.30 | $5.26 | -37% |
| 2024 | $5.26 | $11.1 | +110% |
| 2025 | $11.1 | $31.9 | +189% |
| 2026 YTD | $31.9 | $26.2 | -18% |
STOK's yearly returns have swung widely, from +189% in 2025 to −63% in 2021. It's down 18% so far in 2026.